Quantisnow Logo
Dashboard

SEC Form 25-NSE filed by Philip Morris International Inc

$PM
Medicinal Chemicals and Botanical Products
Health Care
Get the next $PM alert in real time by email
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-33708
Issuer: Philip Morris International Inc.
Exchange: NEW YORK STOCK EXCHANGE LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 120 PARK AVENUE
New York NEW YORK 10017
Telephone number: (917) 663-2000
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
2.750% Notes due 2025
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2025-03-19 By Emily Fuhrman Senior Analyst, Regulation
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PM

DatePrice TargetRatingAnalyst
3/14/2025Hold → Buy
Argus
1/16/2025$140.00Overweight
Morgan Stanley
3/5/2024Buy → Hold
Argus
2/13/2024Sell → Hold
Societe Generale
1/23/2024$105.00 → $86.50Buy → Sell
UBS
11/16/2023$95.00Neutral
Redburn Atlantic
6/20/2023$109.00 → $117.00Neutral → Buy
Citigroup
4/14/2023$114.00Buy
Stifel
More analyst ratings

$PM
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

    Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International Presents at 2025 CAGNY Conference; Reaffirms 2025 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 Consumer Analyst Group of New York (CAGNY) Conference. The event will be webcast live in listen-only mode, beginning at approximately 1:00 p.m. ET, at www.pmi.com/2025cagny and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). Presentation slides will also be available on the same site and the App. An archived copy of the webcast will be available until Friday, March 21, 2025. The presentation will cover: PMI's progress over the past decade to deliver a smoke-free future; t

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

$PM
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PM
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PM
 SEC Filings

See more

$PM
 Leadership Updates

Live Leadership Updates

See more

  • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

$PM
 Financials

Live finance-specific insights

See more

  • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

    Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

  • Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results

    Delivers 2024 Reported Diluted EPS of $4.52, or $6.01 before Canada non-cash impairment of $1.49, compared to $5.02 in 2023 and Adjusted Diluted EPS of $6.57, Representing Growth of 9.3%, and 15.6% on Currency-Neutral Basis Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 fourth-quarter and full-year results.1 "2024 was a remarkable year for PMI. We delivered very strong full-year results driven by the continued growth of IQOS and ZYN in addition to a robust combustibles performance," said Jacek Olczak, Chief Executive Officer. "The long-awaited U.S. FDA authorization of all ZYN nicotine pouches currently marketed in the U.S. is further eviden

    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

$PM
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more